explore -WSS

explore

author：comprehensive 2025-09-06 03:54:53 - browse：4939

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Clinicians often fail to acknowledge the pain caused by long Covid

hotspot

WSS

US soldier in North Korean custody after crossing DMZ line

BridgeBio heart drug succeeds in pivotal study

Some medical students still think black patients feel less pain

Medical students need to learn the potent medicine of empathy

Biden administration sends mixed signals on US soldier who crossed into North Korea

Why you get paid to donate plasma but not blood

knowledge

explore

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Clinicians often fail to acknowledge the pain caused by long Covid

New air purifier tech could be key to improving indoor air quality

Asahi Kasei to buy Calliditas, picking up kidney disease drug

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Guardant Health colon cancer test endorsed by FDA advisory panel

Virginia high school admissions case could be legal follow

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

At least 13 dead in Texas as scorching temps continue

Louisiana bill approved classifying abortion pills as controlled substances

Wikipedia

A Theranos scientist

Decentralized clinical trials need collaboration to achieve wider use

Johnson & Johnson sues to stop Medicare negotiation

Stroke rates rising, especially in working

Achieving telehealth equity for people with hearing loss

US soldier in North Korean custody after crossing DMZ line

hotspot

hotspot

focus

hotspot